Chronic Lymphocytic Leukemia News and Research

RSS
Chronic Lymphocytic Leukemia (CLL) is the most common form of leukemia in adults. According to the American Cancer Society, approximately 8,000 patients will be diagnosed this year. More than 60,000 people in the U.S. currently have CLL. The disease arises in lymphocytes, a type of white blood cell that normally produces antibodies and serves important immune functions. Patients with CLL typically develop symptoms that may progress over a period of years, ultimately producing a generalized depression of immunity, marked increases in the size of spleen, liver and lymph nodes, and impaired production of other normal blood cells. Eventually, these problems may cause life-threatening complications, such as overwhelming infections and fatal bleeding.
New NCCN patient guide for Waldenström's Macroglobulinemia helps make informed treatment decisions

New NCCN patient guide for Waldenström's Macroglobulinemia helps make informed treatment decisions

Enzyme identified in baker's yeast can efficiently annihilate leukemia cells

Enzyme identified in baker's yeast can efficiently annihilate leukemia cells

NCCN publishes new easy-to-understand patient education resources focused on brain cancer

NCCN publishes new easy-to-understand patient education resources focused on brain cancer

Swedish researchers develop new, low-cost method to examine individual leukemia cells

Swedish researchers develop new, low-cost method to examine individual leukemia cells

NCCN publishes new resources to help patients understand treatment options for stomach cancer

NCCN publishes new resources to help patients understand treatment options for stomach cancer

Right dose of CAR T cells and lymphodepletion can achieve good response rates for NHL patients

Right dose of CAR T cells and lymphodepletion can achieve good response rates for NHL patients

BCL-2 inhibitor shows promise in AML patients

BCL-2 inhibitor shows promise in AML patients

T-cell technology could be used to treat ovarian tumors with no adverse effects

T-cell technology could be used to treat ovarian tumors with no adverse effects

NCCN educational resources provide insight for patients with Mycosis Fungoides

NCCN educational resources provide insight for patients with Mycosis Fungoides

Oncologists to present latest research findings at ASCO annual meeting

Oncologists to present latest research findings at ASCO annual meeting

Penn State researchers link mutation in common virus to fatal brain disease

Penn State researchers link mutation in common virus to fatal brain disease

Phase 2 results of AbbVie’s venetoclax in patients with R/R CLL with 17p deletion published in The Lancet Oncology

Phase 2 results of AbbVie’s venetoclax in patients with R/R CLL with 17p deletion published in The Lancet Oncology

NCCN publishes series of patient education materials for Non-Hodgkin's Lymphoma

NCCN publishes series of patient education materials for Non-Hodgkin's Lymphoma

STING agonists developed to induce cellular death in B cell malignancies

STING agonists developed to induce cellular death in B cell malignancies

Xencor begins XmAb5871 Phase 2 trials in patients with IgG4-RD and Systemic Lupus Erythematosus

Xencor begins XmAb5871 Phase 2 trials in patients with IgG4-RD and Systemic Lupus Erythematosus

RUVICA (ibrutinib) capsules approved for treatment-naïve CLL patients

RUVICA (ibrutinib) capsules approved for treatment-naïve CLL patients

EMA grants Orphan Drug Designation to venetoclax for treatment of acute myeloid leukemia

EMA grants Orphan Drug Designation to venetoclax for treatment of acute myeloid leukemia

New mechanism of differentiation may offer novel therapeutic approaches to blood malignancies, solid tumors

New mechanism of differentiation may offer novel therapeutic approaches to blood malignancies, solid tumors

Wnt5a protein acts on tumor-surface proteins to accelerate spread of CLL cells

Wnt5a protein acts on tumor-surface proteins to accelerate spread of CLL cells

ICGC article lays foundation for the coming era of cancer genomic research

ICGC article lays foundation for the coming era of cancer genomic research